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A B S T R A C T
Background: Foods for Special Medical purposes (Phe-free protein substitutes [PS] and low protein foods [LPFs])
are central to successful dietary management of patients with phenylketonuria (PKU). In the UK, PS and LPFs are
prescribed by primary care general practitioners (GPs) and dispensed by high street pharmacists or via home
delivery companies. As patients and carers commonly reported access issues with PS and LPFs through the
National Society for PKU (NSPKU) helpline, the NSPKU collected more information about the extent of pre-
scriptions issues via a questionnaire.
Methods: A cross sectional online survey was carried out consisting of 7 multiple choice and 3 open questions.
The questionnaire was available via the NSPKU website over a 9-month period (15th May 2018–31st January
2019). Carers or patients with PKU were invited to participate if they had any problems accessing PS and LPF.
Results: There were 252 responses. 65% for children and 35% for adults, aged≥18y with PKU. 59% (n=146/
246) of responses described diﬃculties accessing basic LPF (bread, pasta) and 33% (n=81/248) PS. 36%
(n=88/248) said problems had re-occurred> 1y, and 40% (n=99/248) for< 3months. 59% (n=146/246)
had supply issues with LPF and 33% (n=81/246) with PS. 18% (n=42/234) reported that the local NHS
authority had refused, restricted or had a policy to block treatment access; 27% (n=63/234) cited GPs de-
clining requests or restricting prescription amounts. 21% (n=49/234) could not access all their products via a
pharmacy, 40% (n=93/234) said their home delivery system failed, and 15% (n=34/234) of the dispensed
prescribed products were out of date, incorrect, damaged or poor quality. For patients and carers these issues
caused: stress (87%, n=210/241); they considered PKU was not taken seriously by professionals (66%,
n=160/241); they reduced patient access to LPF and PS (53%, n=128/241); and aﬀected the patients' health
(53%, n=128/241).
Discussion: Access to PKU dietary treatment is frequently disrupted for reasons relating to GP prescriptions and
unreliable dispensing and delivery practices. These issues require immediate attention by UK health profes-
sionals in order to create a fairer and more eﬃcient system for everyone.
1. Introduction
Phenylketonuria (PKU) is an autosomal recessive genetic disorder,
that causes deﬁciency of the phenylalanine (Phe) hydroxylase enzyme
leading to an abnormal accumulation of phenylalanine. Individuals
with PKU who are untreated or inadequately treated during infancy and
childhood have profound damage to the developing brain with a very
low intelligence quotient (IQ), hyperactive behaviour with autistic
features, and seizures [1]. In contrast, individuals who are well treated
in early life, have normal intellectual ability but are still at risk of
mental health problems and white matter pathology that adversely
aﬀects motor function that is associated with elevation of Phe at any
time in life [2]. In the UK, the only treatment routinely available for
patients with PKU is a lifelong, Phe restricted diet. Foods such as meat,
ﬁsh, eggs, cheese, nuts, seeds, bread and pasta are high in Phe and must
be avoided. In classical PKU, most patients tolerate< 10 g/day natural
protein [3]. The low Phe diet consists of fruit, some vegetables, sugar
and oils. Even chemical sweeteners, namely aspartame must be avoided
as they contain Phe. ‘Foods for Special Medical Purposes‘(Commission
delegated regulation (EU) 2016/128 of 25 September 2015 supplementing
Regulation (EU) No 609/2013 of the European Parliament and of the
Council as regards the speciﬁc compositional and information requirements
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for food for special medical purposes), including protein substitutes (PS)
and low protein foods (LPF) are an essential part of treatment.
In PKU, PS provide a non /low Phe protein replacement, mainly
based on amino acids and they are usually supplemented with vitamins,
minerals and long chain fatty acids. They prevent protein deﬁciency,
support growth, and their amino acid composition helps optimise me-
tabolic control by promoting anabolism and altering Phe transport both
at gut epithelial level [4] and the blood brain barrier [5]. Special LPF
made from food starches (e.g. bread and pasta), are an important source
of energy, aid satiety, provide variety, help diet acceptability and so
improve adherence. Dietary management should not be attempted
without access to these special dietary products.
Access systems to PS and LPFs varies throughout the world. In most
countries in Europe, PS is paid for by the health service or is available
by insurance [6]. For LPF, reimbursement policies are inconsistent,
varying from full reimbursement in Italy, monthly ﬁnancial allowances
in Belgium, Norway and Denmark, and self-payment in Spain, Ger-
many, The Netherlands and Poland [6]. In the UK, PS and LPFs are
reimbursed via NHS prescription for the dietary management of PKU.
To gain reimbursement status, PS manufacturers must supply evidence
to demonstrate their safety, eﬃcacy, acceptability and tolerance. A
‘recommended list’ of approved products by the Advisory Committee on
Borderline Substances (ACBS) is published as Part XV of the Drug Tariﬀ
and so this guides prescribers (mainly community GPs) about the
suitability of products for PKU. The NSPKU also produces a guide
outlining the maximum number of units per month of LPF which can be
prescribed based on patient age and special circumstances such as
pregnancy.
Over 85% of UK patients with PKU are cared for by specialist hos-
pital centres [3]. The specialist PKU dietitians advise GPs about the
dietary requirements and prescription needs of each patient. Monthly
prescriptions are issued by GPs and they are dispensed either via local
pharmacists (who may oﬀer a home delivery service) or via one of 5
diﬀerent specialist home delivery companies linked to the suppliers of
PS and LPF. In England, only patients aged under 16 years, over
60 years, or pregnant or experiencing other special circumstances are
entitled to ‘free’ prescriptions; others must pay a fee for each item that
is prescribed by their GP (in Northern Ireland, Scotland and Wales
prescriptions are dispensed without charge).
For some time, specialist PKU dietitians in the UK and the NSPKU
have been aware that continuity of supply of ‘Foods for Special Medical
Purposes’ via NHS prescription is problematic for patients with PKU,
with patients being left without supplies leading to disruption to their
essential treatment. In order to ascertain information about the nature
of the access problems and to develop an understanding about the
potential frequency of supply problems, the NSPKU surveyed people
with PKU and their caregivers through an online survey to record access
problems.
2. Material and methods
We carried out a cross sectional online survey. The questionnaire,
which focused on supply issues with low-Phe/Phe-free PS and LPF, was
voluntarily completed and submitted by adults with PKU, parents/
caregivers of children with PKU or health care professionals caring for
their treatment. The questionnaire was placed on the UK NSPKU web-
site, Facebook and twitter accounts between 15th May 2018 and 31st
January 2019. During this nine-month period, respondents could
complete the questionnaire more than once for new or ongoing issues.
Although the study time period was not selected for any reason, the
authors are not aware of any reason why this period would be atypical
or unusual.
This non-validated questionnaire comprised of 10 questions, in-
cluding single choice, multiple choice and 2 open-ended questions: one
question asked for information about respondent postcode (to identify
problems related to area of residence and this is not reported) and the
other asked to describe the problems with access to PS and LPF that
they had experienced. This last question was thematically analysed and
presented in Table 1.
Demographic information was also collected about type of re-
spondent (patient, parent/caregiver, or health professional), age cate-
gorization of patient (child or adult aged ≥18y), male or female, and
patient risk category (aged≤4 years; 5-12y, pregnant, pre-conception).
Respondents answered questions about any dietary products they had
diﬃculty in accessing, the length of time the problem had occurred, the
type of problem that was being experienced and the impact that this
problem had caused. This questionnaire was developed using issues
that had already been reported to the NSPKU helpline patients and
parents/ caregivers.
There were 204 useable responses to the open-ended question.
The whole survey dataset was imported into ‘NVIVO pro’ software
V.11, a programme for qualitative data analysis. Each survey response
was created as a case (allowing responses to be ﬁltered by any char-
acteristics or response which was captured in the survey). Each open-
ended question was created as a node, and the individual responses
within each question were read individually and coded at a very ﬁne
level of detail according to one or more nodes created in response to
emerging patterns in the data.
2.1. Data cleaning and recoding
Data was recoded from Google forms to SPSS format using a variety
of manual transformations and SPSS syntax.
2.2. Analysis
The closed questions (multiple choice and single choice) were
analysed using descriptive statistics only. The open-ended question was
analysed using inductive thematic analysis [7] which centres on iden-
tifying patterns in the text which seem most relevant to the research
objectives. Ideas, comments, statements or ideas which recurred were
coded in NVIVO and these codes were organised into a hierarchical
pattern of nodes with the top-level parent nodes being considered as
probable themes. Codes and themes were reviewed and reﬁned
throughout the analysis process (e.g. merging and splitting codes).
2.3. Ethics
Ethical consent was not sought as it was clariﬁed at the beginning of
the questionnaire that anonymous information may be shared with the
NHS, MPs, government, or health care organisations to improve care for
Table 1
Open-ended question “Do you want to tell us in your own words about the
problem and the eﬀect it has had on you?” This question followed a multiple-
choice question about the type of problem that had been experienced. This
question is described in full as it may have inﬂuenced the responses to the open-
ended question.
What kind of problem are you experiencing? (Tick any that apply to you)
• The NHS authority (e.g. the Clinical Commissioning Group/Health Board) for my
area is refusing or restricting prescribing for PKU products.
• The NHS authority for my area has made a policy that creates an obstacle for getting
my prescriptions.
• The GP will not prescribe the products I want.• The GP restricts the quantity of products I can get.• The GP's receptionist/administrative staﬀ are unhelpful or obstructive.• The GP refuses to allow repeat prescriptions.• My dietitian or consultant will not prescribe the products I need.• I have a prescription, but I cannot get the products I want from the chemist.• I have a delivery service - but the system doesn't work.• I have prescription foods delivered which are out of date, or wrong, or damaged or
poor quality.
• Other
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people with PKU. Potential respondents were also advised that the
NSPKU may publish data from the survey in an anonymized form.
Adults with PKU and caregivers gave their consent by their voluntary
completion and submission of the online questionnaire. If names or
hospitals were mentioned in verbatim abstracts, these were removed in
the presentation of analysis.
3. Results
There were 252 responses to this questionnaire in a 9-month time
scale. Not all responses included an answer to every question. Sixty-ﬁve
per cent (n=160/245) of the responses described prescription issues
with children and 35% (n=86/245) adults. Sixty-ﬁve per cent
(n=160/245) of the responses were about females and 35% (n=86/
245) males. Twenty per cent (n=50/252) of the issues associated with
dietary foods aﬀected children aged ≤4 years; 37% (n=92/252)
children aged 5-12y, 1% (n=2/252) pregnant women, and 4%
(n=10/252) women planning pregnancy. The questionnaires were
completed by parents (37%, n=91/249); patients (25%, n=62/249)
and health professionals on behalf of the patients/carers, 39%, 97 of
249).
Fifty nine per cent (n=146 of 246) of respondents said that they
were having prescription problems with basic LPF (e.g. pasta and
bread), 41% (n=100 of 246) with pre-prepared LPFs (e.g. biscuits,
cakes), and around a third (33%, n=81 of 246) with PS. The rate of
problems for each category was similar between adults and children.
Thirty ﬁve per cent (n=88 of 248) said the problems had re-oc-
curred for> 1 year; 22% (n=55 of 248) over the last year; 19%
(n=47 of 248) over the last 3 months, 13% (n=31 of 248) over the
last 4 weeks and 9% (n=21 of 248) in the last week. The duration of
problems was similar between children and adults.
Table 2 presents types of problems experienced when accessing LPF
and PS.
Thematic analysis of the open-ended questions identiﬁed nine
themes with more than ﬁve coding references, and these were taken as
the main themes. These were: delivery service (n=50), lack of co-or-
dination (n=28), diﬃculty with speciﬁc LPF/PS (n=25), running out
of LPF (including rationing) (n=17), GP related issues (n=17), stress
and hassle (n=14), issues with ordering LPF (n=12), problems with
food supply aﬀecting dietary adherence (n=7); and ignorance about
PKU (n=6).
3.1. Theme 1: Delivery service (n= 50 comments)
There were more responses about children than adults (Table 2).
There were many references to poor standards of home delivery service
including missed deliveries, incomplete deliveries, wrong items sup-
plied, and lack of communication about rescheduling deliveries. Most
of the comments related to one home delivery service (Dial A Chem®).
Caregivers and patients gave detailed feedback about their issues and
frustrations with the home delivery services.
Verbatim extracts from parents and caregivers responses about
delivery service
Sometimes Dial A Chem email us to check if we need things from
this list - sometimes we do not hear from them and we run out of
low protein food. We work hard to maintain control in our 3
children. It is unacceptable to run out of low protein food. No
children should have to go hungry.
.....Almost ran out of protein substitute. Vitaﬂo at Home did a
stock check - only had small supply left but they still aimed to
send it after the child would have run out. The dietitian sorted
this.
......Each month we seem to have a problem with the delivery
service and sometimes the GP. The actual items I get is often
diﬀerent from the ones I have ordered. Items can be missing, but Ta
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there is never an explanation as to why they are missing or if they
will be replaced. I am not sure if this is the GP changing items or if
this is the home delivery changing items? If items are missing,
there is no note to say when they will be replaced or if they will
ever be replaced. Similarly, if they are diﬀerent no note or ex-
planation is given.
3.2. Theme 2: Lack of co-ordination (n= 28 comments)
A major theme was the lack of co-ordination between the key or-
ganisations involved in PKU prescription (GP, GP receptionist, chemist,
ordering and delivery services). There were many instances of confused
communication, leaving patients at risk of no supplies of LPF or PS. One
sub theme also stood out (with 13 coding references), about the role
that dietitians play in acting as the coordinator to rectify any problems
in access to LPF and PS.
Verbatim extracts about lack of co-ordination
Home delivery company failed to deliver infant protein sub-
stitute. The home delivery company did not do an appropriate
stock check. Almost ran out of infant protein substitute. The
hospital organised emergency supplies.
…..The items are not at the chemist as expected or they order
the wrong products from the repeat prescription or I do not get
informed of a supply issue and then we have no supply of protein
supplement or other foods. I decided it would be easier to have
home delivery of the protein supplement, but the GP's team kept
sending the prescription electronically to our local chemist.”
…..No idea when I'll get my food items, often having to chase
them and constantly going backward and forward between GP
and pharmacy to know which actual pharmacy it has been de-
livered to and whether I'll be getting it! The only time I have to
call during open hours is my half an hour lunchtime. I'm actually
trying to get back on diet and have more low protein foods but
this struggle makes everything so much more diﬃcult and it's
why you don't want to be on diet, so you don't have to rely on
prescriptions and GPs.
3.3. Theme 3: Diﬃculty with speciﬁc foods/protein substitute (n= 25
comments)
The caregivers/patients described how not being able to get the
right foods at the right time caused disruption in the provision of
dietary treatment. Inability to access one speciﬁc ﬂavour of PS or being
unable to obtain a speciﬁc LPF that is mixed with a PS (e.g. low protein
yoghurt or milk) may lead to treatment disruption, poor metabolic
control and distress for the patient/caregiver.
Verbatim extracts about diﬃculty with speciﬁc low protein foods
My daughter, if she does not get her bread on time, she is hungry
and then she eats foods she is not allowed that leads to poor
phenylalanine control. I have tried to order fresh bread from Dial
A Chem - they consistently fail to deliver on time. I order fresh
bread from my chemist - they go around the houses to order it -
and they fail to get it to me on time. I am now back with Dial A
Chem. They knew my GP had sent the prescription to the chemist
in error but did nothing to chase this up. They said I should put
my child on packet low protein bread - which she will not eat. My
dietitian has to sort this out for me every time.
......Home delivery service keeps delivering wrong ﬂavour of
PKU Lophlex LQ. It has happened 3 times in 3months. My
daughter will not drink the wrong ﬂavoured protein substitute. It
is very frustrating.
......I am pregnant on very low exchanges and chemist says
they cannot get my Mevalia bread; have taken 2months so far to
give me my Promin pizza mix and are saying that do not know if
they will be able to get it. They then told me they cannot get my
Promin burger mix. All of these are vital items when on 3–4 ex-
changes (3–4 g protein) a day.
3.4. Theme 4: Running out of low protein food /protein substitute (n= 21
comments)
The survey data showed that 47% (n=115 of 247) of responses
referred to running out of LPF and 21% (n=51 of 247) of responses
referred to running out of PS. Many responses referred to people run-
ning out of key LPF for considerable periods or in some cases rationing
their food supplies. There was one sub theme ‘Missing meals or hunger’
(4 coding references) where adults and children had to go without food
or consumed low protein fruit and vegetables only, in the absence of
appropriate LPF.
Verbatim extracts about running out of low protein food
Always running out of essential low protein food. GP will not
supply enough. Dial A Chem delayed order as had no Mevalia
bread. We had to supply food for the patient.
......A little boy aged 18months has recently been unwell/
weight loss, was prescribed SOS 15 (a glucose polymer). A de-
livery was organised with Vitaﬂo at Home. The family ran out of
SOS 15. Vitaﬂo at Home did not deliver as they could not get hold
of mum. They did not inform the dietitian of this.
......I have a daughter who is now 15 y old and is very hungry.
We order foods from the Pharmacy but for the last 2–3months
they are telling us they are out of stock. We have had to beg for
basic items of food. PKU is hard enough, PKU and teenagers is
even harder, to face this battle is soul destroying.
......My food rarely gets to me within 4 weeks after ordering
which means I tend to run out of items such as pasta and rice.
3.5. Theme 5: GP issues (n= 17 comments)
GPs play a key role in patients' access to supplies of LPF and PS. The
most common problems were with the GP receptionists (who often act
as gatekeepers to the prescriptions which are issued). Some recep-
tionists, but also some GPs, did not seem to understand that LPF could
not be purchased in supermarkets (the analogy to gluten free food, for
people with coeliac disease, was mentioned in responses, and gluten
free foods are widely available in shops and supermarkets, unlike LPFs).
GPs sometimes refused to prescribe the appropriate range or quantity of
LPFs, and it appeared that cost was a barrier.
Verbatim extracts about GP related issues
I've had to move GP surgeries three times in 1 year to try to ﬁnd
one that would prescribe me products and refer me to the meta-
bolic clinic.
......My daughter is 17 now and I never get what I ask for,
quantity wise. They feel they know what my child consumes per
month therefore re-write my order for me. It's always the ones
who type the prescriptions up. Numerous times a year I have to go
in and speak to receptionist to get them to write a note in my
daughter's ﬁle but it reoccurs again and again
......3 times my foods have been wiped oﬀ my list and the
reason is due to them saying it is all gluten free. I have had to go
in the receptionists and explain what PKU is and that it is LPF not
gluten free
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3.6. Theme 6: Stress and hassle (n= 14 comments)
Survey data indicated that 85% (n=210 of 247) of responses said
their problems were stressful, 77% (n=191 of 247) time consuming,
and 66% (n=162 of 247), said they think that PKU is not taken ser-
iously by professionals. Forty-seven per cent (n=116 of 247) found the
problems depressing or degrading and 15% (n=37 of 247) said the
problems made them want to give up on their diet. Some said they faced
continual worry, stress and demands on their time in chasing up issues
to do with the supply of LPF and PS.
Verbatim extracts about stress and hassle associated with dietary
prescriptions
I have constant stress & anxiety. Feel unsupported, overlooked &
alone. Consultant aware but not been able to sort. Deliveries ar-
rive late & my son has days without supplies eating just fruit &
veg at times & always hungry.
......It causes a lot of stress and worries because we know how
we feel and act when we can't keep our levels down.
......It is stressful every month when being told by chemist
they can't get certain items, when I ring manufacturers, they say
no problems in supply or tell chemist to order direct and it would
come the next day but chemist won't.
......It's really worrying when you've been waiting for supple-
ments for a week and they still don't arrive to be told there is a
manufacturing problem and you've only got a couple of days'
supply left. The emotional rollercoaster that this causes is really
worrying.
3.7. Theme 7: Issues with ordering low protein food (12 comments)
Ordering PKU food was sometimes problematic and it was not un-
common for patients to ﬁnd that products were out of stock (or to be
informed that they were) and not to have full ﬂexibility in what they
could order (e.g. minimum or maximum amounts). Survey data showed
that 52% (n=129 of 247) said this aﬀected the variety in the diet.
Verbatim extracts about issues with ordering LPF
I have found a document that states I am allowed 50 units per
month of prescription items (excluding supplements and milk
substitutes), but sometimes my prescription requests are refused
without reason.
......Always a problem on the prescription i.e. wrong item or
only 1 of bread, milk etc. when we have asked numerous times for
larger quantities… the receptionist thinks that I'm over reacting
as I could get these items in supermarkets which we know isn't
the case as my son has PKU only 5 exchanges so most foods are
prescription.
3.8. Theme 8: Problems with food supply eﬀecting adherence (n= 7
comments)
The unpredictability of supply and unavailability of key PKU food
items causes the low Phe diet to be particularly arduous and it led to
inadvertent low dietary adherence, poor metabolic control and even
cessation of dietary treatment.
Verbatim extracts about issues with food supply aﬀecting ad-
herence
I went back on diet, did really well but got fed up with GPs re-
stricting and refusing to give me the prescription. This happened
a few times; also if I got products I got asked if I couldn't have a
cheaper version. I got fed up ﬁghting a losing battle with GPs that
I came oﬀ diet and stayed oﬀ it.
......Miscommunication between the home delivery company
and the family. The family do not speak English as their ﬁrst
language and have 2 small boys with severe/classical PKU. Lack
of calories leads to poor metabolic control. They were allowed to
run out of low protein milk (through home delivery not checking
stock levels) which caused very high blood Phe levels.
......I got told by the receptionist that I am no longer allowed
to put orders in for food products as they have a limit and I'm only
allowed basics due to cost such as bread, pasta etc. As I have
classical PKU I feel it has aﬀected me because I know my levels
are high and I am trying to get back on the diet desperately but
every time when I think I am sorted something like this happens.
……. I did try to arrange appointment to see my GP to make him
aware but couldn't get it….
3.9. Theme 9: Ignorance of PKU (n= 6 comments)
Responses described how they had to ‘educate’ health professionals
(e.g. GPs, receptionists, and pharmacists) about their low Phe diet. One
sub theme ‘entitlement to PKU foods’ (2 coding references) relates to
speciﬁc knowledge about what foods people with PKU are entitled to
obtain on prescription.
Verbatim extracts about ignorance of PKU
Just started university and the student GP is not understanding at
all about what is needed; just makes starting uni {university}
more stressful and complicated than it needed to be, having to
explain to health care professionals what PKU is - it's hard enough
explaining to everyone else.
4. Discussion
Although this survey was not based on a random sample of the PKU
population, but rather a self-selected sample from visitors to the NSPKU
website who were invited to complete a questionnaire if they were
experiencing problems with prescriptions, it illustrates the issues, bar-
riers and frustrations that patients with PKU have in accessing essential
PS and LPF to enable them to adhere with dietary management in the
UK. Dietary product prescription refusal, obstacles that caused delays in
products being dispensed and received by the end users, and failure of
health professionals within the community, pharmacists or home de-
livery companies to support patients on low Phe diets all led to patient
hunger, treatment disruption, unintentional dietary non-adherence, and
poor blood Phe control, and it even led to treatment abandonment. Poor
metabolic control can negatively impact development and behaviour in
childhood, mental health and neurological status in teenagers and
adults, as well as potentially causing birth defects in pregnant women
such as cardiac defects and microcephaly and low IQ in the oﬀspring
[8–10]. Over 60% of the prescription problems related to people in high
risk categories based on age, pregnancy and women planning preg-
nancy.
It was particularly worrying that both the NHS authority (e.g. the
Clinical Commissioning Group or Health Board) and the GPs had re-
fused to prescribe PS and LPF or limited the quantity of products that
patients had access to. Refusal of LPF prescription was commonly as-
sociated with misunderstanding or consideration that some LPFs such
as low protein cake mixes, or cereals bars were luxury items. However,
if followed by GPs, the NSPKU guidelines suggest monthly upper limits
on the number of LPF's that can be prescribed. These guidelines help
ensure expenditure is controlled on LPF items, enable patients to re-
ceive enough LPFs to meet energy requirements but they limit excess
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amounts. The problem of PS and LPF access was more prevalent in
adults with PKU, even though in the UK, lifelong dietary treatment has
been recommended since 1993, [11] and the recent PKU European
guidelines strengthened this recommendation with further supporting
evidence [2,12]. In our survey 15% of the respondents said access
problems made them want to abandon their PKU diet and some re-
spondents even described how the frustrations of accessing ‘Foods for
Special Medical Purposes’ had led to cessation of dietary treatment.
They had to live with food insecurity, knowing that their supplies of PS
or LPF's was limited or of uncertain availability. Unfortunately, adult
patients who stop the PKU diet may experience poor executive func-
tioning, information processing (reaction times, attention) and low
mood (increased inhibition, anxiety, depression and low self-esteem)
compared with adults who have continued Phe restriction throughout
life and healthy controls [13–17]. A UK NHS system that permits in-
dividual GPs and clinical commissioning groups to refuse access to the
only permitted and commissioned treatment of patients with PKU is
ﬂawed.
Failure of the home delivery services to provide a reliable service for
patients with PKU was highlighted as an issue by many patients and
caregivers. Home delivery services were used more by children than
adults with PKU. Whilst home delivery services have been shown to be
safer [18], the survey responses (mainly associated with one home
delivery service) indicate that they are not always reliable. Lack of
communication with caregivers or patients, and poor co-ordination
with GP practices or pharmacists, leaving patients without LPF and PS
supplies were common occurrences. Some responses described re-
ceiving damaged, short shelf-life or out of date LPF. Patients using high-
street pharmacists reported similar diﬃculties. None of the home de-
livery services were able to supply the entire range of LPF and PS.
Multiple supply sources lead to confusion and ineﬃciency and these
have been reported previously [19].
Accessing ‘Foods for Special Medical Purposes’ was a stressful pro-
cess (cited in 85% of the responses), with many responses identifying
that this activity was time consuming and time wasting. Many said they
considered their prescription problems were not taken seriously by
health care professionals. It was not uncommon for patients or parents
to feel humiliated by staﬀ within primary care or frustrated by the
cumbersome system. A survey conducted in Scotland also identiﬁed the
negative experiences and obstructions which people with PKU have
experienced when attempting to access prescribable LPF [20]. It is
diﬃcult for adults and caregivers to ﬁnd time to teach and commu-
nicate community health professionals about their (or their child's)
dietary requirement when they may be working and have limited
availability to speak to the GP practice team.
It is time to re-evaluate how patients with PKU access their LPF and
PS in the UK. Supply systems should be introduced whereby patients/
caregivers have minimum contact with health professionals who have
little knowledge or experience of caring for PKU, and these non-spe-
cialists should not take decisions on the appropriateness of specialist
dietary products for an individual patient. The specialist centres, par-
ticularly specialist dietitians, should play a more prominent and direct
role in the provision of PS and LPF, although they will need additional
resources in order to conduct this task. It should be examined if all
specialist dietary products could be delivered from a single ‘hub’, sup-
ported by all the dietary companies. Also, an annual programmed
‘credit card’ system speciﬁcally for LPF could be explored, enabling
patients to order LPF online, oﬀering them ﬂexibility, choice and im-
mediate access to LPF.
5. Limitations
Our sample of respondents were self-selected rather than drawn
from a random sample, and it is unknown to what extent the problems
reported are reﬂective of the entire population of patients with PKU. It
is also possible that the survey respondents were more informed or
vocal about PKU issues than the general PKU population as many were
users of the NSPKU website. This survey speciﬁcally collected in-
formation about problems with access to PS and LPF rather than col-
lecting information about any systems or services that worked well. The
prescriptions issues were complex and qualitative research methods
(such as one to one interviews) would be appropriate for a deeper
understanding of patients' and carers' experiences. We did not collect
any quantitative data about blood Phe control or neurocognitive out-
comes. We also did not seek the views of the GPs, pharmacists or home
delivery service providers.
6. Conclusions
A fundamental review of how specialist dietary products are pre-
scribed, supplied and controlled for patients with PKU is urgently
needed. Consideration should be given to specialist dietitians providing
prescriptions for patients with PKU patients, directing responsibility
from a community driven system to the specialist treatment centres.
Otherwise, the disconnect between those who control treatment access
and those who understand it will continue. The delivery systems for LPF
are fragmented. A system overhaul with cooperation by all suppliers to
consider one central delivery system, which is properly resourced must
be considered to improve service reliability and reduce the patient and
caregiver anxiety associated with PS and LPF access. Further research is
also needed amongst people with PKU, with larger random samples, to
gain reliable estimates of the frequency of these problems in the PKU
population.
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